Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 225 articles:
HTML format



Single Articles


    October 2021
  1. KIRKHAM AA, King K, Joy AA, Pelletier AB, et al
    Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise
    BMC Cancer. 2021;21:1093.
    PubMed     Abstract available


  2. TSUKAMOTO F, Arihiro K, Takahashi M, Ito KI, et al
    Multicenter retrospective study on the use of Curebest 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
    BMC Cancer. 2021;21:1077.
    PubMed     Abstract available


    September 2021
  3. LEE J, Jung JH, Kim WW, Kang B, et al
    Short-term serial assessment of electronic patient-reported outcome for depression and anxiety in breast Cancer.
    BMC Cancer. 2021;21:1065.
    PubMed     Abstract available


  4. LIN Y, Zhou X, Peng W, Wu J, et al
    Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
    BMC Cancer. 2021;21:1062.
    PubMed     Abstract available


  5. ABEBE E, Tollesa T, Assefa M, Tilahun Z, et al
    Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study.
    BMC Cancer. 2021;21:1052.
    PubMed     Abstract available


  6. AKINYEMIJU T, Jones K, Gupta A, Oyekunle T, et al
    Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.
    BMC Cancer. 2021;21:1051.
    PubMed     Abstract available


  7. RAGALA MEA, El Hilaly J, Amaadour L, Omari M, et al
    Validation of Mini-Mental Adjustment to Cancer scale in a Moroccan sample of breast cancer women.
    BMC Cancer. 2021;21:1042.
    PubMed     Abstract available


  8. JAKOBSEN M, Kolodziejczyk C, Jensen MS, Poulsen PB, et al
    Cardiovascular disease in women with breast cancer - a nationwide cohort study.
    BMC Cancer. 2021;21:1040.
    PubMed     Abstract available


  9. STURKEN C, Mobus V, Milde-Langosch K, Schmatloch S, et al
    Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
    BMC Cancer. 2021;21:1024.
    PubMed    


  10. ZHANG X, Pang X, Zhang Z, Liu Q, et al
    Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
    BMC Cancer. 2021;21:1026.
    PubMed     Abstract available


  11. TAY MRJ, Wong CJ, Aw HZ
    Prevalence and associations of axillary web syndrome in Asian women after breast cancer surgery undergoing a community-based cancer rehabilitation program.
    BMC Cancer. 2021;21:1019.
    PubMed     Abstract available


  12. DIMITROVA D, Naghavi B, Richter R, Nasser S, et al
    Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
    BMC Cancer. 2021;21:1018.
    PubMed     Abstract available


  13. NIU T, Wu Z, Xiao W
    Uev1A promotes breast cancer cell migration by up-regulating CT45A expression via the AKT pathway.
    BMC Cancer. 2021;21:1012.
    PubMed     Abstract available


  14. FUKUI J, White K, Frankland TB, Oshiro C, et al
    Weight changes according to treatment in a diverse cohort of breast cancer patients.
    BMC Cancer. 2021;21:1005.
    PubMed     Abstract available


  15. MARCELINO AC, Gozzi B, Cardoso-Filho C, Machado H, et al
    Race disparities in mortality by breast cancer from 2000 to 2017 in Sao Paulo, Brazil: a population-based retrospective study.
    BMC Cancer. 2021;21:998.
    PubMed     Abstract available


    August 2021
  16. SZWIEC M, Tomiczek-Szwiec J, Kluzniak W, Wokolorczyk D, et al
    Genetic predisposition to male breast cancer in Poland.
    BMC Cancer. 2021;21:975.
    PubMed     Abstract available


  17. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
    Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
    BMC Cancer. 2021;21:967.
    PubMed     Abstract available


  18. LI Y, Ma L
    Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer.
    BMC Cancer. 2021;21:965.
    PubMed     Abstract available


  19. DAI YH, Wang YF, Shen PC, Lo CH, et al
    Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer.
    BMC Cancer. 2021;21:945.
    PubMed     Abstract available


  20. MOON SY, Lee H, Kim S, Hong JH, et al
    Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    BMC Cancer. 2021;21:931.
    PubMed     Abstract available


  21. STURKEN C, Mobus V, Milde-Langosch K, Schmatloch S, et al
    TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
    BMC Cancer. 2021;21:920.
    PubMed     Abstract available


  22. ZHANG Y, Zhang D, Meng Q, Liu Z, et al
    Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.
    BMC Cancer. 2021;21:918.
    PubMed     Abstract available


  23. SU TP, Huang JS, Chang PH, Lui KW, et al
    Prospective comparison of early interim (18)F-FDG-PET with (18)F-FLT-PET for predicting treatment response and survival in metastatic breast cancer.
    BMC Cancer. 2021;21:908.
    PubMed     Abstract available


  24. DE CALUWE A, Buisseret L, Poortmans P, Van Gestel D, et al
    Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
    BMC Cancer. 2021;21:899.
    PubMed     Abstract available


  25. CHEBET JJ, Ehiri JE, McClelland DJ, Taren D, et al
    Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis.
    BMC Cancer. 2021;21:902.
    PubMed     Abstract available


  26. ALGEO N, Bennett K, Connolly D
    Rehabilitation interventions to support return to work for women with breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:895.
    PubMed     Abstract available


  27. CHAN RJ, Cooper B, Gordon L, Hart N, et al
    Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery.
    BMC Cancer. 2021;21:883.
    PubMed     Abstract available


  28. WANG Y, Men X, Gu Y, Wang H, et al
    Haplotype analysis on correlation between transcription factor 7-like 2 gene polymorphism and breast cancer risk.
    BMC Cancer. 2021;21:885.
    PubMed     Abstract available


    July 2021
  29. WANG G, Zhang S, Wang M, Liu L, et al
    Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis.
    BMC Cancer. 2021;21:875.
    PubMed     Abstract available


  30. HAJJ A, Hachem R, Khoury R, Hallit S, et al
    Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study.
    BMC Cancer. 2021;21:872.
    PubMed     Abstract available


  31. WU W, Chen J, Deng H, Jin L, et al
    Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
    BMC Cancer. 2021;21:862.
    PubMed     Abstract available


  32. TURKISTANI S, Sugita BM, Fadda P, Marchi R, et al
    A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
    BMC Cancer. 2021;21:861.
    PubMed     Abstract available


  33. JANG MK, Han J, Kim SH, Ko YH, et al
    Comparison of fatigue and fatigability correlates in Korean breast cancer survivors and differences in associations with anxiety, depression, sleep disturbance, and endocrine symptoms: a randomized controlled trial.
    BMC Cancer. 2021;21:855.
    PubMed     Abstract available


  34. LEI YY, Ho SC, Kwok C, Cheng A, et al
    Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort.
    BMC Cancer. 2021;21:839.
    PubMed     Abstract available


  35. LU H, Zha S, Zhang W, Wang Q, et al
    A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
    BMC Cancer. 2021;21:830.
    PubMed     Abstract available


  36. VIALA M, Firmin N, Touraine C, Pouderoux S, et al
    Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer.
    BMC Cancer. 2021;21:815.
    PubMed     Abstract available


  37. LI S, Wu J, Huang O, He J, et al
    Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
    BMC Cancer. 2021;21:807.
    PubMed     Abstract available


  38. SONG D, Hu Y, Diao B, Miao R, et al
    Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
    BMC Cancer. 2021;21:798.
    PubMed     Abstract available


  39. NAKAYAMA T, Yoshinami T, Yasojima H, Kittaka N, et al
    Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
    BMC Cancer. 2021;21:795.
    PubMed     Abstract available


    June 2021
  40. JIAO X, Wang B, Feng C, Song S, et al
    Formin-like protein 2 promotes cell proliferation by a p27-related mechanism in human breast cancer cells.
    BMC Cancer. 2021;21:760.
    PubMed     Abstract available


  41. ZHAO Q, Hughes R, Neupane B, Mickle K, et al
    Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
    BMC Cancer. 2021;21:758.
    PubMed     Abstract available


  42. GAO J, Wang S, Zhang Z, Li J, et al
    Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.
    BMC Cancer. 2021;21:745.
    PubMed     Abstract available


  43. HE C, Zhu WX, Tang Y, Bai Y, et al
    Knowledge of a cancer diagnosis is a protective factor for the survival of patients with breast cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:739.
    PubMed     Abstract available


  44. WANG K, Jin X, Wang W, Yu X, et al
    The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    BMC Cancer. 2021;21:728.
    PubMed     Abstract available


  45. HALLER H, Voiss P, Cramer H, Paul A, et al
    The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women's response to integrative breast cancer treatment.
    BMC Cancer. 2021;21:724.
    PubMed     Abstract available


  46. GUO L, Xie G, Wang R, Yang L, et al
    Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
    BMC Cancer. 2021;21:717.
    PubMed     Abstract available


  47. DONG J, Sun Q, Pan Y, Lu N, et al
    Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:700.
    PubMed     Abstract available


  48. SUN M, Tang C, Liu J, Jiang W, et al
    Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.
    BMC Cancer. 2021;21:696.
    PubMed     Abstract available


  49. BREIDENBACH C, Wesselmann S, Sibert NT, Ortmann O, et al
    Use of social service counseling by cancer patients: an analysis of quality assurance data of 6339 breast cancer patients from 13 certified centers in Germany treated between 2015 and 2017.
    BMC Cancer. 2021;21:671.
    PubMed     Abstract available


  50. BORRERO-GARCIA LD, Del Mar Maldonado M, Medina-Velazquez J, Troche-Torres AL, et al
    Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    BMC Cancer. 2021;21:652.
    PubMed     Abstract available


    May 2021
  51. WOO J, Oh SJ, Song JY, Chae BJ, et al
    Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    BMC Cancer. 2021;21:647.
    PubMed     Abstract available


  52. HUANG S, Hu P, Lakowski TM
    Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    BMC Cancer. 2021;21:648.
    PubMed     Abstract available


  53. WANG D, Wei G, Ma J, Cheng S, et al
    Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
    BMC Cancer. 2021;21:645.
    PubMed     Abstract available


  54. FOSTER M, Niedzwiedz CL
    Associations between multimorbidity and depression among breast cancer survivors within the UK Biobank cohort: a cross-sectional study.
    BMC Cancer. 2021;21:650.
    PubMed     Abstract available


  55. LIU Y, Teng L, Fu S, Wang G, et al
    Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    BMC Cancer. 2021;21:644.
    PubMed     Abstract available


  56. MCWILLIAMS L, Woof VG, Donnelly LS, Howell A, et al
    Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?
    BMC Cancer. 2021;21:637.
    PubMed     Abstract available


  57. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:596.
    PubMed     Abstract available


  58. ANWAR SL, Cahyono R, Prabowo D, Avanti WS, et al
    Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
    BMC Cancer. 2021;21:590.
    PubMed     Abstract available


  59. HAN P, Zhu J, Feng G, Wang Z, et al
    Characterization of alternative splicing events and prognostic signatures in breast cancer.
    BMC Cancer. 2021;21:587.
    PubMed     Abstract available


  60. ZOGRAFOS E, Korakiti AM, Andrikopoulou A, Rellias I, et al
    Germline mutations in a clinic-based series of pregnancy associated breast cancer patients.
    BMC Cancer. 2021;21:572.
    PubMed     Abstract available


  61. ZHANG Y, Asad S, Weber Z, Tallman D, et al
    Genomic features of rapid versus late relapse in triple negative breast cancer.
    BMC Cancer. 2021;21:568.
    PubMed     Abstract available


  62. CHAN CWH, Law BMH, Ng MSN, Wong CCY, et al
    Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review.
    BMC Cancer. 2021;21:570.
    PubMed     Abstract available


  63. ZHANG M, Wang B, Liu N, Wang H, et al
    Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.
    BMC Cancer. 2021;21:565.
    PubMed     Abstract available


  64. NITTALA MR, Mundra EK, Packianathan S, Mehta D, et al
    The Will Rogers phenomenon, breast cancer and race.
    BMC Cancer. 2021;21:554.
    PubMed     Abstract available


  65. MILLS MN, Naz A, Thawani C, Walker C, et al
    Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    BMC Cancer. 2021;21:552.
    PubMed     Abstract available


  66. WANG Y, Wang Y, Chen R, Tang Z, et al
    Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients.
    BMC Cancer. 2021;21:542.
    PubMed     Abstract available


  67. SOOD R, Masalu N, Connolly RM, Chao CA, et al
    Invasive breast Cancer treatment in Tanzania: landscape assessment to prepare for implementation of standardized treatment guidelines.
    BMC Cancer. 2021;21:527.
    PubMed     Abstract available


  68. WANG B, Wang H, Zhao A, Zhang M, et al
    Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits.
    BMC Cancer. 2021;21:523.
    PubMed     Abstract available


  69. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available


  70. WOODS LM, Rachet B, Morris M, Bhaskaran K, et al
    Are socio-economic inequalities in breast cancer survival explained by peri-diagnostic factors?
    BMC Cancer. 2021;21:485.
    PubMed     Abstract available


  71. EOM KY, van Londen GJ, Li J, Dahman B, et al
    Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform.
    BMC Cancer. 2021;21:487.
    PubMed     Abstract available


    April 2021
  72. YUAN Y, Xiao WW, Xie WH, Li RZ, et al
    Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.
    BMC Cancer. 2021;21:479.
    PubMed     Abstract available


  73. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available


  74. MAJED SO, Mustafa SA
    MACE-Seq-based coding RNA and TrueQuant-based small RNA profile in breast cancer: tumor-suppressive miRNA-1275 identified as a novel marker.
    BMC Cancer. 2021;21:473.
    PubMed     Abstract available


  75. YU Y, Wang Z, Wei Z, Yu B, et al
    Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.
    BMC Cancer. 2021;21:466.
    PubMed     Abstract available


  76. ANDRIKOPOULOU A, Apostolidou K, Chatzinikolaou S, Bletsa G, et al
    Trastuzumab administration during pregnancy: un update.
    BMC Cancer. 2021;21:463.
    PubMed     Abstract available


  77. LIU H, Shi W, Jin Z, Zhuo R, et al
    Global, regional, and national mortality trends of female breast cancer by risk factor, 1990-2017.
    BMC Cancer. 2021;21:459.
    PubMed     Abstract available


  78. NAJAFI S, Ansari M, Kaveh V, Haghighat S, et al
    Comparing the efficacy and side-effects of PDLASTA(R) (Pegfilgrastim) with PDGRASTIM(R) (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
    BMC Cancer. 2021;21:454.
    PubMed     Abstract available


  79. HOUSE BJ, Kwon MJ, Schaefer JM, Barth CW, et al
    Clinically relevant dual probe difference specimen imaging (DDSI) protocol for freshly resected breast cancer specimen staining.
    BMC Cancer. 2021;21:440.
    PubMed     Abstract available


  80. JANEVA S, Parris TZ, Nasic S, De Lara S, et al
    Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    BMC Cancer. 2021;21:439.
    PubMed     Abstract available


  81. YAMAGUCHI J, Moriuchi H, Ueda T, Kawashita Y, et al
    Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    BMC Cancer. 2021;21:434.
    PubMed     Abstract available


  82. TAN Z, Zou Y, Zhu M, Luo Z, et al
    Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer.
    BMC Cancer. 2021;21:409.
    PubMed     Abstract available


  83. LV R, Yang G, Huang Y, Wang Y, et al
    Dosimetric effects of supine immobilization devices on the skin in intensity-modulated radiation therapy for breast cancer: a retrospective study.
    BMC Cancer. 2021;21:384.
    PubMed     Abstract available


  84. LIANG G, Ma W, Zhao Y, Liu E, et al
    Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
    BMC Cancer. 2021;21:362.
    PubMed     Abstract available


  85. LIU Z, Liu J, Liu R, Xue M, et al
    Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification.
    BMC Cancer. 2021;21:367.
    PubMed     Abstract available


  86. REECE JC, Neal EFG, Nguyen P, McIntosh JG, et al
    Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review.
    BMC Cancer. 2021;21:373.
    PubMed     Abstract available


  87. AREFAN D, Hausler RM, Sumkin JH, Sun M, et al
    Predicting cell invasion in breast tumor microenvironment from radiological imaging phenotypes.
    BMC Cancer. 2021;21:370.
    PubMed     Abstract available


  88. CABIOGLU N, Onder S, Oner G, Karatay H, et al
    TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
    BMC Cancer. 2021;21:357.
    PubMed     Abstract available


    March 2021
  89. COLOMBIE M, Jezequel P, Rubeaux M, Frenel JS, et al
    The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients.
    BMC Cancer. 2021;21:333.
    PubMed     Abstract available


  90. CHEN S, Han Y, Ouyang Q, Lu J, et al
    Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
    BMC Cancer. 2021;21:341.
    PubMed     Abstract available


  91. CHU CN, Hu KC, Wu RS, Bau DT, et al
    Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy.
    BMC Cancer. 2021;21:330.
    PubMed     Abstract available


  92. CHEN L, Dong Y, Pan Y, Zhang Y, et al
    Identification and development of an independent immune-related genes prognostic model for breast cancer.
    BMC Cancer. 2021;21:329.
    PubMed     Abstract available


  93. FALCICCHIO C, Di Lallo D, Fabi A, Bonucci A, et al
    Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study.
    BMC Cancer. 2021;21:311.
    PubMed     Abstract available


  94. ALOMRAN R, White M, Bruce M, Bressel M, et al
    Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
    BMC Cancer. 2021;21:303.
    PubMed     Abstract available


  95. SANDVEI MS, Opdahl S, Valla M, Lagiou P, et al
    The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study.
    BMC Cancer. 2021;21:299.
    PubMed     Abstract available


  96. JAYASINGHE R, Fernando A, Jayarajah U, Seneviratne S, et al
    Post treatment quality of life among Sri Lankan women with breast cancer.
    BMC Cancer. 2021;21:305.
    PubMed     Abstract available


  97. YUAN Q, Hou J, He Y, Liao Y, et al
    Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.
    BMC Cancer. 2021;21:293.
    PubMed     Abstract available


  98. KURODA H, Jamiyan T, Yamaguchi R, Kakumoto A, et al
    Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
    BMC Cancer. 2021;21:286.
    PubMed     Abstract available


  99. LIN B, Liu C, Shi E, Jin Q, et al
    MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4.
    BMC Cancer. 2021;21:275.
    PubMed     Abstract available


  100. ZEPPELLINI A, Galimberti S, Leone BE, Pacifico C, et al
    Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
    BMC Cancer. 2021;21:260.
    PubMed     Abstract available


  101. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available


  102. LI C, Tao C, Bai T, Li Z, et al
    Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.
    BMC Cancer. 2021;21:261.
    PubMed     Abstract available


  103. JI L, Cheng L, Zhu X, Gao Y, et al
    Risk and prognostic factors of breast cancer with liver metastases.
    BMC Cancer. 2021;21:238.
    PubMed     Abstract available


  104. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
    BMC Cancer. 2021;21:239.
    PubMed     Abstract available


  105. HERRMANN C, Morant R, Walser E, Mousavi M, et al
    Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects.
    BMC Cancer. 2021;21:229.
    PubMed     Abstract available


  106. WIND A, Hartman ED, Van Eekeren RRJP, Wijn RPWF, et al
    Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences.
    BMC Cancer. 2021;21:231.
    PubMed     Abstract available


  107. LIU X, Zheng D, Wu Y, Luo C, et al
    Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China.
    BMC Cancer. 2021;21:226.
    PubMed     Abstract available


  108. HUANG Z, Zhou X, Tong Y, Zhu L, et al
    Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study.
    BMC Cancer. 2021;21:222.
    PubMed     Abstract available


  109. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available


  110. TOPNO R, Singh I, Kumar M, Agarwal P, et al
    Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    BMC Cancer. 2021;21:220.
    PubMed     Abstract available


  111. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available


  112. ZHANG SL, Song J, Wang YR, Guo YJ, et al
    Short-term outcomes and safety of radiotherapy for immediate breast reconstruction with autologous flap transfer following breast-conserving surgery.
    BMC Cancer. 2021;21:214.
    PubMed     Abstract available


  113. OLOW AK, Veer LV', Wolf DM
    Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.
    BMC Cancer. 2021;21:212.
    PubMed     Abstract available


    February 2021
  114. ZHAO F, Hao Z, Zhong Y, Xu Y, et al
    Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation.
    BMC Cancer. 2021;21:194.
    PubMed     Abstract available


  115. YU L, Shi Q, Jin Y, Liu Z, et al
    Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
    BMC Cancer. 2021;21:195.
    PubMed     Abstract available


  116. HUANG CC, Tsai YF, Liu CY, Chao TC, et al
    Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    BMC Cancer. 2021;21:199.
    PubMed     Abstract available


  117. MATSON DR, Denu RA, Zasadil LM, Burkard ME, et al
    High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
    BMC Cancer. 2021;21:186.
    PubMed     Abstract available


  118. TSUJI K, Matsuoka YJ, Ochi E
    High-intensity interval training in breast cancer survivors: a systematic review.
    BMC Cancer. 2021;21:184.
    PubMed     Abstract available


  119. BERGER K, Rhost S, Rafnsdottir S, Hughes E, et al
    Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
    BMC Cancer. 2021;21:185.
    PubMed     Abstract available


  120. LEE J, Park HY, Kim WW, Lee JJ, et al
    Natural course of fat necrosis after breast reconstruction: a 10-year follow-up study.
    BMC Cancer. 2021;21:166.
    PubMed     Abstract available


  121. LIU J, Zheng X, Han Z, Lin S, et al
    Clinical characteristics and overall survival prognostic nomogram for invasive cribriform carcinoma of breast: a SEER population-based analysis.
    BMC Cancer. 2021;21:168.
    PubMed     Abstract available


  122. JIANG H, Li H
    Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:149.
    PubMed     Abstract available


  123. TAN W, Liu M, Wang L, Guo Y, et al
    Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer.
    BMC Cancer. 2021;21:126.
    PubMed     Abstract available


  124. JIAO D, Zhang J, Zhu J, Guo X, et al
    Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
    BMC Cancer. 2021;21:138.
    PubMed     Abstract available


  125. LIU M, Liu S, Yang L, Wang S, et al
    Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:118.
    PubMed     Abstract available


  126. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available


  127. YANG Q, Zhong X, Zhang W, Luo T, et al
    Cost-effectiveness of different surgical treatment approaches for early breast cancer: a retrospective matched cohort study from China.
    BMC Cancer. 2021;21:107.
    PubMed     Abstract available


  128. KAWAMOTO T, Shikama N, Kurokawa C, Hara N, et al
    A prospective feasibility study of a 1-mm bolus for postmastectomy radiotherapy.
    BMC Cancer. 2021;21:109.
    PubMed     Abstract available


    January 2021
  129. BEACHLER DC, de Luise C, Jamal-Allial A, Yin R, et al
    Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
    BMC Cancer. 2021;21:97.
    PubMed     Abstract available


  130. WHITEHEAD I, Irwin GW, Bannon F, Coles CE, et al
    The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
    BMC Cancer. 2021;21:90.
    PubMed     Abstract available


  131. JUNG SM, Jeon BJ, Woo J, Ryu JM, et al
    Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?
    BMC Cancer. 2021;21:88.
    PubMed     Abstract available


  132. HUO X, Li J, Zhao F, Ren D, et al
    The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:78.
    PubMed     Abstract available


  133. EVANGELISTA AF, Oliveira RJ, O Silva VA, D C Vieira RA, et al
    Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    BMC Cancer. 2021;21:76.
    PubMed     Abstract available


  134. BASET Z, Abdul-Ghafar J, Parpio YN, Haidary AM, et al
    Risk factors of breast cancer among patients in a tertiary care hospitals in Afghanistan: a case control study.
    BMC Cancer. 2021;21:71.
    PubMed     Abstract available


  135. GENG SK, Fu SM, Ma SH, Fu YP, et al
    Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:68.
    PubMed     Abstract available


  136. OO KK, Kamolhan T, Soni A, Thongchot S, et al
    Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.
    BMC Cancer. 2021;21:65.
    PubMed     Abstract available


  137. FIROUZABADI D, Dehghanian A, Rezvani A, Mahmoudi L, et al
    Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    BMC Cancer. 2021;21:47.
    PubMed     Abstract available


  138. NAKATSUKASA K, Niikura N, Kashiwabara K, Amemiya T, et al
    Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
    BMC Cancer. 2021;21:34.
    PubMed     Abstract available


  139. MOSLEMI M, Moradi Y, Dehghanbanadaki H, Afkhami H, et al
    The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:27.
    PubMed     Abstract available


    December 2020
  140. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    BMC Cancer. 2020;20:1215.
    PubMed     Abstract available


  141. DESA DE, Strawderman RL, Wu W, Hill RL, et al
    Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction.
    BMC Cancer. 2020;20:1217.
    PubMed     Abstract available


  142. KIM JY, Jung EJ, Kim JM, Lee HS, et al
    Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis.
    BMC Cancer. 2020;20:1206.
    PubMed     Abstract available


  143. BAO H, Wang L, Brown M, Zhang M, et al
    A nationally quasi-experimental study to assess the impact of partial organized breast and cervical cancer screening programme on participation and inequalities.
    BMC Cancer. 2020;20:1191.
    PubMed     Abstract available


  144. KROZ M, Reif M, Glinz A, Berger B, et al
    Correction to: Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive coho
    BMC Cancer. 2020;20:1174.
    PubMed     Abstract available


  145. TORRES-ROMAN JS, Martinez-Herrera JF, Carioli G, Ybaseta-Medina J, et al
    Breast cancer mortality trends in Peruvian women.
    BMC Cancer. 2020;20:1173.
    PubMed     Abstract available


    November 2020
  146. BISWAS A, Mukherjee G, Kondaiah P, Desai KV, et al
    Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
    BMC Cancer. 2020;20:1159.
    PubMed     Abstract available


  147. SUN GY, Wen G, Zhang YJ, Tang Y, et al
    Radiotherapy plays an important role in improving the survival outcome in patients with T1-2N1M0 breast cancer - a joint analysis of 4262 real world cases from two institutions.
    BMC Cancer. 2020;20:1155.
    PubMed     Abstract available


  148. ZHANG Z, Zheng Q, Liu Y, Sun L, et al
    Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells.
    BMC Cancer. 2020;20:1158.
    PubMed     Abstract available


  149. GAO ZH, Li CX, Liu M, Jiang JY, et al
    Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    BMC Cancer. 2020;20:1150.
    PubMed     Abstract available


  150. ZHANG L, Tang R, Deng JP, Zhang WW, et al
    The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer.
    BMC Cancer. 2020;20:1146.
    PubMed     Abstract available


  151. WANG J, Tang Y, Jing H, Sun G, et al
    Risk stratification for prediction of locoregional recurrence in patients with pathologic T1-2N0 breast cancer after mastectomy.
    BMC Cancer. 2020;20:1132.
    PubMed     Abstract available


  152. BERGER E, Maitre N, Romana Mancini F, Baglietto L, et al
    The impact of lifecourse socio-economic position and individual social mobility on breast cancer risk.
    BMC Cancer. 2020;20:1138.
    PubMed     Abstract available


  153. SHIRMOHAMMADI E, Ebrahimi SS, Farshchi A, Salimi M, et al
    Correction to: The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.
    BMC Cancer. 2020;20:1126.
    PubMed     Abstract available


  154. KAPLAN HG, Malmgren JA, Atwood MK
    Breast cancer distant recurrence lead time interval by detection method in an institutional cohort.
    BMC Cancer. 2020;20:1124.
    PubMed     Abstract available


  155. MARINELLI O, Romagnoli E, Maggi F, Nabissi M, et al
    Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(-)Rb wild-type and knock-down in breast cancer cell lines.
    BMC Cancer. 2020;20:1119.
    PubMed     Abstract available


  156. PU S, Wang K, Liu Y, Liao X, et al
    Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT).
    BMC Cancer. 2020;20:1120.
    PubMed     Abstract available


  157. REZNICZEK GA, Giger-Pabst U, Thaher O, Tempfer CB, et al
    Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.
    BMC Cancer. 2020;20:1122.
    PubMed     Abstract available


  158. LEE IH, Lee SJ, Lee J, Jung JH, et al
    Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2020;20:1106.
    PubMed     Abstract available


  159. LI X, Zhang X, Liu J, Shen Y, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    BMC Cancer. 2020;20:1102.
    PubMed     Abstract available


  160. FENG R, Jing J, Zhang X, Li M, et al
    Adherence to post-surgery follow-up assessment and its association with sociodemographic and disease characteristics in patients with breast cancer in Central China.
    BMC Cancer. 2020;20:1098.
    PubMed     Abstract available


  161. PITTALIS C, Panteli E, Schouten E, Magongwa I, et al
    Breast and cervical cancer screening services in Malawi: a systematic review.
    BMC Cancer. 2020;20:1101.
    PubMed     Abstract available


  162. HERNANDEZ VARGAS JA, Ramirez Barbosa PX, Gil Quijano AM, Valbuena AM, et al
    Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: an administrative registry data analysis.
    BMC Cancer. 2020;20:1097.
    PubMed     Abstract available


  163. NG CWQ, Lim JNW, Liu J, Hartman M, et al
    Presentation of breast cancer, help seeking behaviour and experience of patients in their cancer journey in Singapore: a qualitative study.
    BMC Cancer. 2020;20:1080.
    PubMed     Abstract available


  164. MALIK R, Vera N, Dayal C, Choudhari A, et al
    Factors associated with breast cancer awareness and breast self-examination in Fiji and Kashmir India - a cross-sectional study.
    BMC Cancer. 2020;20:1078.
    PubMed     Abstract available


  165. RING A, Kaur P, Lang JE
    EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    BMC Cancer. 2020;20:1076.
    PubMed     Abstract available


  166. TRIVINO JC, Ceba A, Rubio-Solsona E, Serra D, et al
    Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study.
    BMC Cancer. 2020;20:1079.
    PubMed     Abstract available


  167. MUNOZ-ALCARAZ MN, Perula-de-Torres LA, Serrano-Merino J, Jimenez-Vilchez AJ, et al
    Efficacy and efficiency of a new therapeutic approach based on activity-oriented proprioceptive antiedema therapy (TAPA) for edema reduction and improved occupational performance in the rehabilitation of breast cancer-related arm lymphedema in women:
    BMC Cancer. 2020;20:1074.
    PubMed     Abstract available


  168. NI M, Zhou X, Liu J, Yu H, et al
    Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI.
    BMC Cancer. 2020;20:1073.
    PubMed     Abstract available


  169. YANAI K, Fujii T, Horiguchi J, Nakazawa Y, et al
    Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer.
    BMC Cancer. 2020;20:1068.
    PubMed     Abstract available


  170. TENTLER JJ, Lang J, Capasso A, Kim DJ, et al
    RX-5902, a novel beta-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    BMC Cancer. 2020;20:1063.
    PubMed     Abstract available


  171. LIM GB, Kim YA, Seo JH, Lee HJ, et al
    Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel.
    BMC Cancer. 2020;20:1052.
    PubMed     Abstract available


  172. KWONG A, Shin VY, Ho CYS, Au CH, et al
    Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
    BMC Cancer. 2020;20:1053.
    PubMed     Abstract available


  173. XU H, Liu Z, Shi H, Wang C, et al
    Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:1051.
    PubMed     Abstract available


    October 2020
  174. ENNOUR-IDRISSI K, Dragic D, Durocher F, Diorio C, et al
    Epigenome-wide DNA methylation and risk of breast cancer: a systematic review.
    BMC Cancer. 2020;20:1048.
    PubMed     Abstract available


  175. SHAMSHIRIAN A, Aref AR, Yip GW, Ebrahimi Warkiani M, et al
    Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:1049.
    PubMed     Abstract available


  176. WEI C, Li X
    Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    BMC Cancer. 2020;20:1042.
    PubMed     Abstract available


  177. LEI YY, Ho SC, Kwok C, Cheng A, et al
    Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study.
    BMC Cancer. 2020;20:1013.
    PubMed     Abstract available


  178. AGBEKO AE, Arthur J, Bayuo J, Kaburi BB, et al
    Seeking healthcare at their 'right' time; the iterative decision process for women with breast cancer.
    BMC Cancer. 2020;20:1011.
    PubMed     Abstract available


  179. MA T, Liu H, Liu Y, Liu T, et al
    USP6NL mediated by LINC00689/miR-142-3p promotes the development of triple-negative breast cancer.
    BMC Cancer. 2020;20:998.
    PubMed     Abstract available


  180. LI X, Zhou C, Wu Y, Chen X, et al
    Relationship between formulaic breast volume and risk of breast cancer based on linear measurements.
    BMC Cancer. 2020;20:989.
    PubMed     Abstract available


  181. ZHAO W, Wu L, Zhao A, Zhang M, et al
    A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
    BMC Cancer. 2020;20:982.
    PubMed     Abstract available


  182. RAINEY L, van der Waal D, Broeders MJM
    Dutch women's intended participation in a risk-based breast cancer screening and prevention programme: a survey study identifying preferences, facilitators and barriers.
    BMC Cancer. 2020;20:965.
    PubMed     Abstract available


  183. XIA L, Li F, Qiu J, Feng Z, et al
    Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1.
    BMC Cancer. 2020;20:949.
    PubMed     Abstract available


  184. CULBERTSON MG, Bennett K, Kelly CM, Sharp L, et al
    The psychosocial determinants of quality of life in breast cancer survivors: a scoping review.
    BMC Cancer. 2020;20:948.
    PubMed     Abstract available


  185. NIU S, Huang J, Li J, Liu X, et al
    Application of ultrasound artificial intelligence in the differential diagnosis between benign and malignant breast lesions of BI-RADS 4A.
    BMC Cancer. 2020;20:959.
    PubMed     Abstract available


  186. AKAHANE T, Kanomata N, Harada O, Yamashita T, et al
    Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
    BMC Cancer. 2020;20:944.
    PubMed     Abstract available


    September 2020
  187. LEE J, Jung JH, Kim WW, Park CS, et al
    Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma.
    BMC Cancer. 2020;20:934.
    PubMed     Abstract available


  188. INARI H, Teruya N, Kishi M, Horii R, et al
    Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis.
    BMC Cancer. 2020;20:932.
    PubMed     Abstract available


  189. FUJITA M, Imadome K, Somasundaram V, Kawanishi M, et al
    Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
    BMC Cancer. 2020;20:929.
    PubMed     Abstract available


  190. YANG H, Xu Y, Zhao Y, Yin J, et al
    The role of tissue elasticity in the differential diagnosis of benign and malignant breast lesions using shear wave elastography.
    BMC Cancer. 2020;20:930.
    PubMed     Abstract available


    August 2020
  191. HICKS BM, Busby J, Mills K, O'Neil FA, et al
    Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study.
    BMC Cancer. 2020;20:804.
    PubMed     Abstract available


  192. ALEXEEV SM, Khorinko AV, Mukhametshina GZ, Shelepen KG, et al
    Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
    BMC Cancer. 2020;20:783.
    PubMed     Abstract available


  193. ZHONG L, Xie L, Yang Z, Li L, et al
    Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    BMC Cancer. 2020;20:766.
    PubMed     Abstract available


  194. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
    Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    BMC Cancer. 2020;20:747.
    PubMed     Abstract available


  195. GWYNNE WD, Shakeel MS, Girgis-Gabardo A, Kim KH, et al
    Antagonists of the serotonin receptor 5A target human breast tumor initiating cells.
    BMC Cancer. 2020;20:724.
    PubMed     Abstract available


    July 2020
  196. PENG C, DuPre N, VoPham T, Heng YJ, et al
    Low dose environmental radon exposure and breast tumor gene expression.
    BMC Cancer. 2020;20:695.
    PubMed     Abstract available


  197. ABSIL L, Journe F, Larsimont D, Body JJ, et al
    Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
    BMC Cancer. 2020;20:640.
    PubMed     Abstract available


  198. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available


  199. RUHNAU J, Parczyk J, Danker K, Eickholt B, et al
    Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
    BMC Cancer. 2020;20:617.
    PubMed     Abstract available


    June 2020
  200. TORGBENU E, Luckett T, Buhagiar MA, Chang S, et al
    Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:604.
    PubMed     Abstract available


  201. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed     Abstract available


  202. PU Q, Lv YR, Dong K, Geng WW, et al
    Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
    BMC Cancer. 2020;20:583.
    PubMed     Abstract available


  203. FRENCH DP, Astley S, Brentnall AR, Cuzick J, et al
    What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420).
    BMC Cancer. 2020;20:570.
    PubMed     Abstract available


  204. BOLDES T, Merenbakh-Lamin K, Journo S, Shachar E, et al
    R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers.
    BMC Cancer. 2020;20:531.
    PubMed     Abstract available


  205. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    BMC Cancer. 2020;20:513.
    PubMed     Abstract available


  206. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available


    May 2020
  207. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available


  208. LIU H, Zhan H, Sun D
    Comparison of (99m)Tc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions.
    BMC Cancer. 2020;20:463.
    PubMed     Abstract available


  209. WOOF VG, Ruane H, French DP, Ulph F, et al
    The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women.
    BMC Cancer. 2020;20:452.
    PubMed     Abstract available


  210. LIN J, Lin KJ, Wang YF, Huang LH, et al
    Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy.
    BMC Cancer. 2020;20:451.
    PubMed     Abstract available


  211. FAHLBUSCH SS, Keil S, Epplen JT, Zanker KS, et al
    Comparison of hybrid clones derived from human breast epithelial cells and three different cancer cell lines regarding in vitro cancer stem/ initiating cell properties.
    BMC Cancer. 2020;20:446.
    PubMed     Abstract available


  212. EGELAND NG, Jonsdottir K, Aure MR, Sahlberg K, et al
    MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers.
    BMC Cancer. 2020;20:377.
    PubMed     Abstract available


  213. PARK JH, Lee DH, Kim SI, Kim NK, et al
    Moderate to vigorous physical activity participation associated with better quality of life among breast and colorectal cancer survivors in Korea.
    BMC Cancer. 2020;20:365.
    PubMed     Abstract available


    April 2020
  214. NYHOF BB, Wright FC, Look Hong NJ, Groot G, et al
    Identifying opportunities to support patient-centred care for ductal carcinoma in situ: qualitative interviews with clinicians.
    BMC Cancer. 2020;20:364.
    PubMed     Abstract available


  215. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    PubMed     Abstract available


  216. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
    Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC Cancer. 2020;20:325.
    PubMed     Abstract available


    March 2020
  217. WATANABE K, Katayama K, Yoshioka T, Narimatsu H, et al
    Impact of individual background on the unmet needs of cancer survivors and caregivers - a mixed-methods analysis.
    BMC Cancer. 2020;20:263.
    PubMed     Abstract available


  218. MOSS C, Haire A, Cahill F, Enting D, et al
    Guy's cancer cohort - real world evidence for cancer pathways.
    BMC Cancer. 2020;20:187.
    PubMed     Abstract available


  219. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    BMC Cancer. 2020;20:197.
    PubMed     Abstract available


    February 2020
  220. PESSOA-PEREIRA D, Evangelista AF, Causin RL, da Costa Vieira RA, et al
    miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    BMC Cancer. 2020;20:143.
    PubMed     Abstract available


  221. HU G, Hu G, Zhang C, Lin X, et al
    Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    BMC Cancer. 2020;20:136.
    PubMed     Abstract available


  222. DETTOGNI RS, Stur E, Laus AC, da Costa Vieira RA, et al
    Potential biomarkers of ductal carcinoma in situ progression.
    BMC Cancer. 2020;20:119.
    PubMed     Abstract available


    January 2020
  223. MANOHARAN V, Karunanayake EH, Tennekoon KH, De Silva S, et al
    Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    BMC Cancer. 2020;20:72.
    PubMed     Abstract available


  224. HA JH, Hong KY, Lee HB, Moon HG, et al
    Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching.
    BMC Cancer. 2020;20:78.
    PubMed     Abstract available


  225. NAWAS AF, Kanchwala M, Thomas-Jardin SE, Dahl H, et al
    IL-1-conferred gene expression pattern in ERalpha(+) BCa and AR(+) PCa cells is intrinsic to ERalpha(-) BCa and AR(-) PCa cells and promotes cell survival.
    BMC Cancer. 2020;20:46.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: